Caremo Successfully Obtains National High-Tech Enterprise Certification!

In accordance with the Administrative Measures for the Recognition of High and New Technology Enterprises (GuokeFa [2016] No. 32) and the Work Guidelines for the Recognition and Management of High and New Technology Enterprises (Guoke Fa [2016] No. 195), Nanjing Caremo Biomedical Co., Ltd. has been officially certified as a National High-Tech Enterprise.

This certification not only signifies authoritative recognition of Caremo's achievements in technological innovation, patent portfolios, R&D investment, growth metrics, and talent structure, but also highlights the company's robust R&D capabilities and enhances its core competitiveness.

Leveraging our existing platform, we aspire to collaborate with global biotech and pharmaceutical partners across the entire R&D value chain—from target validation to commercialization. By addressing clients' differentiated needs and flexibly adapting to diverse collaboration models, Caremo aims to provide comprehensive, integrated, end-to-end solutions encompassing drug discovery and production services, delivering full-spectrum technological and industrial support.

· About Caremo

Founded in June 2020 by Dr. Zhang Xiaoqing—a National "Ten Thousand Talent Program" expert (awarded by the Organization Department of the CPC Central Committee) and former founder of Huawai Pharmaceutical Group—Nanjing Caremo Bio-Pharmaceutical Co., Ltd. is headquartered in Nanjing. The company is dedicated to delivering customizable, one-stop R&D solutions for global biotech and pharmaceutical enterprises, covering:

Drug screening & discovery
Cell biology studies
Pharmacology & pharmacodynamics
Drug metabolism analysis
Non-clinical safety evaluation
CMC services
Clinical trial management
Customized development
Novel drug incubation investment

Our full-lifecycle project management system supports partners from product initiation through commercialization, accelerating drug development timelines. Caremo currently operates:
✓ A 350-member R&D team with extensive expertise in preclinical research and CMC
✓ 11,000+ sqm of laboratories compliant with China and US regulatory standards, including chemical and BSL-2 laboratories
✓ 400+ advanced analytical instruments
✓ 35,000+ sqm GLP-compliant R&D headquarters under construction